Hemab Therapeutics Holdings, Inc. (COAG) AI Stock Analysis

Hemab Therapeutics Holdings, Inc.

(NASDAQ:COAG)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Negative Factors

Hemab Therapeutics Holdings, Inc. (COAG) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $1.94B
Dividend Yield: ―
Average Volume (3M): 459.13K
Price to Earnings (P/E): -31.6
Beta (1Y): -0.85
Revenue Growth: ―
EPS Growth: ―
Country: US
Employees: 59
Sector: General
Sector Strength: 55
Industry: Biotechnology

Hemab Therapeutics Holdings, Inc. Business Overview & Revenue Model

Company Description

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients th...

Hemab Therapeutics Holdings, Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

COAG against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADMA	83Outperform	$2.56B	15.85	39.59%	―	8.04%	-18.53%
PHAR	65Neutral	$861.21M	34.69	8.96%	―	6.67%	2242.07%
SRPT	58Neutral	$1.97B	-12.93	-9.96%	―	-20.44%	-349.84%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
STOK	52Neutral	$1.70B	-6.94	-67.30%	―	-86.28%	-634.38%
QURE	49Neutral	$1.72B	-6.15	-111.96%	―	30.24%	-3.25%

* General Sector Average

Performance Comparison

COAG and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
COAG	Hemab Therapeutics Holdings, Inc.	41.45	7.45	21.91%
SRPT	Sarepta Therapeutics Inc.	18.62	2.42	14.94%
QURE	uniQure N.V.	24.83	-5.61	-18.43%
ADMA	ADMA Biologics Inc	11.41	-3.22	-22.01%
STOK	Stoke Therapeutics	26.29	0.95	3.75%
PHAR	Pharming Group Nv	12.23	-0.93	-7.07%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Hemab Therapeutics Holdings, Inc. AI Stock Analysis